While the current antipsychotic medications have profoundly impacted the treatment of schizophrenia over the past 50 years, the newer atypical antipsychotics have not fulfilled initial expectations, and enormous challenges remain in long-term treatment of this debilitating disease. In particular, improved treatment of the negative symptoms and cognitive dysfunction in schizophrenia which greatly impact overall morbidity is needed. In this review we will briefly discuss the current pipeline of drugs for schizophrenia, outlining many of the strategies and targets currently under investigation for the development of new schizophrenia drugs. Many of these compounds have great potential as augmenting agents in the treatment of negative symptoms and cognition. In addition, we will highlight the importance of developing new paradigms for drug discovery in schizophrenia and call for an increased role of academic scientists in discovering and validating novel drug targets. Indeed, recent breakthroughs in genetic studies of schizophrenia are allowing for the development of hypothesis-driven approaches for discovering possible disease-modifying drugs for schizophrenia. Thus, this is an exciting and pivotal time for the development of truly novel approaches to drug development and treatment of complex disorders like schizophrenia.
Introduction
Since the discovery of the antipsychotic effect of chlorpromazine more than 50 years ago, 1 the number of antipsychotic medications available for the treatment of schizophrenia has tremendously increased. With the development of the first-generation antipsychotics, or typical antipsychotics, it was for the first time possible to treat the 'positive' symptoms of schizophrenia, such as delusions and hallucinations, leading to the deinstitutionalization of the world's mentally ill. The typical antipsychotic drugs, however, are generally not thought to be effective at treating the 'negative' symptoms, such as anhedonia and lack of motivation, and cognitive dysfunction of schizophrenia and have a high burden of extrapyramidal side effects (EPS). 2 The reintroduction of clozapine in the United States in 1989, issued in the current era of atypical or second-generation antipsychotics. Atypical antipsychotic drugs are differentiated from typical antipsychotic drugs by virtue of a relative lack of EPS and serum prolactin elevation as compared with typical antipsychotic drugs. Clozapine itself has become the 'gold standard' antipsychotic medication because of its absence of debilitating extrapyramidal side effects and its demonstrated clinical superiority in treatment-resistant schizophrenia 3 and suicidality. 4 Whether clozapine has any significant beneficial effect on negative symptoms and cognition is unclear. 2, 5 Clozapine, however, is associated with its own set of serious side effects including weight gain, diabetes and an increased risk of seizures and agranulocytosis. 6 The documented superiority of clozapine 3, 7 over other antipsychotic drugs has led to an intense effort over the past 15-20 years to develop clozapine-like atypical antipsychotics that are safer and better tolerated than clozapine. As such, multiple atypical and pseudo-atypical antipsychotic drugs, including risperidone, olanzapine, quetiapine and ziprasidone have been developed. Expectations that these agents comprised a breakthrough in the treatment of schizophrenia, especially with regards to improvements in negative symptoms and cognition were initially high. 8 These expectations, however, have not been realized. 9, 10 While there is evidence that most of the new medications offer, at best, modest advantages over the typical antipsychotic drugs with regard to improvement in negative symptoms, cognitive impairment and functional capacity, the improvements are not consistent among studies. 2, 11, 12 In addition, the atypical antipsychotics carry their own substantial side-effect burden, specifically weight gain and the metabolic syndrome. 13, 14 While the introduction of antipsychotic medications has had a profound effect on the treatment of schizophrenia over the past 50 years, and the atypical antipsychotic drugs have provided a larger and more diverse armamentarium of treatment options, the advances that have been made since the discovery of the antipsychotic properties of chlorpromazine have been small and incremental. Thus, enormous challenges remain in the long-term treatment of this debilitating disease and continuing with the current paradigms of drug discovery is unlikely to produce significant advances. 15, 16 It is therefore important to continue to pursue diverse molecular targets for discovering new antipsychotic compounds and to devise novel paradigms for drug discovery in schizophrenia.
A fundamental barrier to the discovery and development of novel treatments for schizophrenia remains that our level of understanding of the biological processes involved in schizophrenia is not sufficient to predict the therapeutic value of novel drug targets. 16 Thus, unvalidated targets are frequently left unpursued by the pharmaceutical industry and, frequently, companies have focused on alterations of existing medications (that is, separating enantiomers or marketing active metabolites; for example 9-OHrisperidone or paliperidone), 17 finding additional compounds that hit known and validated targets ('me too' drugs; for example ORG-5222 or asenapine), 18 and on gaining approval on new indications for already marketed drugs 19 (for example clozapine for suicide in schizophrenia 4 ). These methods, however, cannot continue indefinitely as the number of such possibilities is limited and thus it is critical to find new approaches to drug development. Interestingly, many of the atypicals will soon be going off patent, beginning with the launch of generic risperidone in 2007. Thus, there is significant interest and urgency within the pharmaceutical industry and among schizophrenia basic scientists and clinicians in developing safer and more-effective treatments for schizophrenia.
In this review we will briefly discuss the current pipeline of drugs for schizophrenia (Table 1) and will outline many of the strategies and targets currently under investigation for the development of new schizophrenia drugs. In addition, we will highlight the importance of developing new paradigms for drug discovery in schizophrenia and call for an increased role of academic scientists in discovering and validating novel drug targets. 15, 16 Symptom domains in schizophrenia It has been proposed that new therapeutics in schizophrenia should target narrower ranges of symptoms rather than to try to develop the perfect 'monotherapy' for a complex disorder. 20 This proposal is grounded in the complexity of schizophrenia which is characterized by severe and variable symptoms in a number of symptom domains, including positive symptoms such as hallucinations, delusions, and disorganized thought, negative symptoms such as a lack of motivation and interest, and a blunted affective range, and symptoms of cognitive impairments in attention, working memory, and a variety of executive functions. All of the currently approved drugs for the treatment of schizophrenia, however, were developed and are most efficacious at treating the positive symptoms of the disease while the negative symptoms and cognitive impairments actually contribute disproportionately more to the long-term disability in patients with schizophrenia. 21 It is clear that patients who exhibit significant negative symptoms have particularly poor functional capacity and quality of life 22, 23 and while there was optimism that the atypicals comprised a breakthrough in the treatment of negative symptoms, 8 this prospect has not been realized to a clinically significant degree. 9, 10 Despite the limitations of current medications and the morbidity associated with negative symptoms, no drug has received Food and Drug Administration (FDA) approval for an indication of negative symptoms. As such, the National Institutes of Mental Health (NIMH) has recently released a consensus statement on the negative symptoms of schizophrenia 24 highlighting that negative symptoms represent a distinct and clinically important entity that should be a focus of future drug development efforts.
In addition to negative symptoms, schizophrenia is also characterized by significant cognitive impairments. For example, patients with schizophrenia have been documented to have problems with attention, working memory and learning and a variety of executive-level functions including abstract thinking and problem solving. 25, 26 Indeed, a meta-analysis of cognitive deficits suggested that indices of cognitive deficits are much better predictors of functional outcome than indices from any other symptom domain. 27 However, these cognitive deficits have been relatively unimproved by currently approved antipsychotic drugs, though some evidence exists for the superiority of atypicals such as olanzapine and risperidone over typicals. 5, 28, 29 Owing to the remaining need for improved treatment of the cognitive impairments in schizophrenia the National Institutes of Mental Health (NIMH) has begun a joint academic and industry initiative termed MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) to facilitate the development of better treatments targeted at cognition. 30 Thus, while psychopharmacologic research in schizophrenia aims for the development of new antipsychotic drugs with a more rapid onset of action, lower risk of side effects and improved efficacy in the domains of negative and cognitive symptoms it is unlikely that a single drug will have the desired effect across all of these domains. Optimal treatment of Dopamine antags  Neurogen Corporation  NDR  D2, D1, 5-HT2A  GMC-283  Merck KGaA  NDR  D2, D3  PD-157695  Pfizer  NDR  D2, 5-HT, D4  HMR-2934  Sanofi-Aventis  NDR  D2, 5-HT1A, D3  PD-158771  Pfizer  NDR  D2, 5-HT2A, mAChR  Org-23366  Akzo Nobel  NDR  D1  D1 agonist D2 antagonist  Eli Lilly  Preclinical  D1  BSF-78438  Abbott  NDR  D1  LE-300  Sanofi-Aventis  NDR  D3  BP4.879a  Bioprojet  NDR  D3  SB-277011  GlaxoSmithKline  NDR  D3 PD-157533 Pfizer NDR schizophrenia in the near future will likely rely on polypharmacy with individualized treatment aimed at the multidimensional nature of this disorder.
Current antipsychotics and drugs in phase III clinical trials
There are a number of theories regarding the mechanism of action of antipsychotic drugs, 16, 31, 32 though the precise mechanism remains incompletely understood. Briefly, it is important that all of the currently approved antipsychotic drugs have at least some affinity for the dopamine D 2 receptor and for the typicals there is a strong correlation between the therapeutic doses and their binding affinity for D 2 receptors. 33, 34 In addition, positron emission tomography (PET) studies have demonstrated that antipsychotic effects are associated with a striatal D 2 receptor occupancy of 65-70% 35, 36 with occupancy levels greater than 80% associated with increased risk of EPS. 36 The basis of the 'atypicality' of newer medications, likewise is incompletely understood, though a primary theory is the serotonin-dopamine antagonism theory 37 which posits that a higher ratio of serotonin 5-HT 2A receptor affinity to dopamine D 2 receptor affinity explains the enhanced efficacy and reduced EPS burden seen with the atypicals. This hypothesis is consistent with the atypical features of risperidone, olanzapine, quetiapine, ziprasidone and the recently approved paliperidone (9-OHrisperidone). A third class of antipsychotics are the dopamine partial agonists, with aripiprazole being the only one currently approved for clinical use. 32 It is thought that the relative lack of EPS seen with clinical use of aripiprazole is due to its functional selectivity at D 2 receptors protecting against excessive blockade of the D 2 system. 32, 38, 39 Thus, while the mechanism of action of currently available antipsychotics is not fully known, D 2 receptor occupancy (either by antagonism or functionally selective agonism) is important for the treatment of the positive symptoms of schizophrenia with some modulation of this D 2 blockade, likely increased dopamine transmission in the cortex and hippocampus, being important for both why atypical antipsychotics and aripiprazole have a reduced EPS burden and somewhat higher efficacy at treating negative symptoms and cognitive dysfunction. 40 The drugs in the pipeline for the treatment of schizophrenia that are currently in Phase III clinical trials appear to have the same mechanism of action of already available agents. Asenapine (formerly known as ORG-5222; now discontinued from clinical development) and iloperidone are antagonists at D 2 and 5-HT 2A and many other receptors (Table 2) and bifeprunox is a D 2 partial agonist. A new drug 31 Additionally, clozapine's active metabolite, N-desmethylclozapine, is a potent partial agonist at dopamine 41 and muscarinic 42, 43 receptors. This extremely complex pharmacological profile is thought to underlie both clozapine's superior clinical efficacy and its spectrum of serious side effects. 3 As such, much effort in antipsychotic drug development over the past two decades has been to create clozapine-like drugs that bind to fewer targets and thus reduce the side-effect burden by targeting only the appropriate receptors. As will be reviewed below, attempts thus far to target clozapine's 'magic receptor', however, have largely been unsuccessful. Indeed, it appears that the paradigm of 'one-disease one-target' that became the dominant approach in the pharmaceutical industry with the advent of molecular biological techniques, while ideal from a scientific and practical perspective, may not be suitable for complex psychiatric diseases such as schizophrenia. In recent years, a number of authors have proposed that designing selectively non-selective drugs that interact with several molecular targets (coined 'magic shotguns') 31 will lead to more effective medications for a variety of complex disorders. 31, 44, 45 We will briefly review the individual molecular targets that may have a role in these 'magic shotguns' or in a polypharmacy approach targeting the various clinical symptom domains of schizophrenia (Table 3) . Where available, references to key review articles are provided. In addition, we will highlight how selective compounds have generally been ineffective as monotherapy for schizophrenia. Indeed, many of the drugs in Phase I, Phase II and preclinical development for the treatment of schizophrenia represent a shift from targeting D 2 and 5-HT 2A receptors to targeting other monoaminergic receptors and other neurotransmitter receptors, though results in small clinical trials have generally been less than encouraging.
Additional dopaminergic approaches
In addition to the key role of dopamine D 2 receptors in antipsychotic function, compounds selective for other dopamine receptors have been explored as potential treatments for schizophrenia.
Dopamine D 1 receptors
Significant evidence exists for the importance of dopamine D 1 receptors in the pathophysiology of schizophrenia, particularly having a role in cognitive dysfunction. 46 For example, chronic blockade of D 2 receptors results in a downregulation of D 1 receptors in the prefrontal cortex and consequently produces severe impairments in working memory in nonhuman primates. 47 This downregulation of D 1 receptors may explain why long-term treatment with typical antipsychotic drugs may contribute to the cognitive dysfunction in schizophrenia. In fact, direct blockade of D 1 receptors with selective antagonists, predicted to have antipsychotic effects in early preclinical models, showed no antipsychotic efficacy in clinical trials and may have exacerbated symptoms in some patients. 48, 49 Thus, current efforts are focused on a possible role of D 1 receptor agonists in treating the cognitive dysfunction in schizophrenia. Indeed, short-term administration of a D 1 selective agonist, ABT-431, reversed the cognitive deficits in monkeys treated chronically with a D 2 receptor antagonist. 47 Other studies have also shown cognitive enhancement with a partial agonist of the D 1 receptor and selective, full D 1 receptor agonists in non-human primates. 50, 51 Thus, novel compounds targeted at stimulating D 1 receptor signaling either directly or indirectly may be of immense value in treating the cognitive deficits in schizophrenia, though some potential pitfalls may need to be overcome. First, in addition to insufficient D 1 receptor activity, excessive D 1 activity such as that resulting from acute stress may also be deleterious to cognition. 52 In addition, chronic treatment with a D 1 receptor agonist may actually lead to downregulation of the D 1 receptor potentially worsening cognition in the long term. Thus, an optimized level of D 1 receptor activation may be required to realize full cognitive benefits, 52 which may be accomplished by partial agonists or an intermittent pattern of administration. 47, 53 Dopamine D 3 receptors D 3 receptors are structurally similar to D 2 receptors and thus most antipsychotics have relatively high affinity for these receptors. 54 As such, significant effort has been placed on investigating the potential role of the D 3 receptor as a target for drug development in schizophrenia. Indeed, a post-mortem study of drug-free patients with schizophrenia demonstrated elevated D 3 receptor levels in contrast to normal D 3 receptor levels in patients treated with antipsychotic medications. 55 In addition, a D 3 receptor partial agonist was able to block the increase in locomotor activity in mice induced by N-methyl-D-aspartate (NMDA) glutamate receptors antagonists, such as phencyclidine or ketamine, a frequently used preclinical model of psychosis. 56 As such, multiple selective dopamine D 3 agents are currently in clinical trials for the treatment of schizophrenia. For example, A-437203 is currently undergoing Phase II trials, although clinical data are not yet available 54 as is SB-773812 (Clinical Trials @.gov identifier NCT00259870). Development of another agent, PNU-177864, which is a partial agonist at D 3 receptors appears to have been stopped due to safety concerns. 57 Thus, the potential antipsychotic efficacy of selective D 3 receptor agonism and antagonism remains unknown at this time, though some data suggest the benefit of D 3 receptor partial agonists in the treatment of Parkinson's disease and drug addiction. 58 Additional preclinical studies have also suggested a role of D 3 receptor antagonists in improving negative symptoms 59 and working memory, 60 though clinical evidence is unavailable.
Dopamine D 4 receptors
When the dopamine D 4 receptor was initially cloned it was also found that clozapine had higher affinity for this receptor than for D 2 receptors creating significant speculation that the D 4 receptor may be clozapine's 'magic receptor'. 61 Further support of a role of D 4 receptors in schizophrenia came from postmortem 63, 64 In addition, a trial of finanserin, a potent antagonist at both D 4 and serotonin 5-HT 2A receptors, also found no evidence of antipsychotic efficacy versus placebo in patients with schizophrenia. 65 These clinical trial failures have suggested that selective D 4 receptor antagonism alone is not responsible for the antipsychotic efficacy of clozapine; however, it is possible that D 4 receptor blockade in collaboration with action at other neurotransmitter receptors may be clinically beneficial. Indeed, studies of the physiological roles for the D 4 receptor are finding that D 4 receptors may play an important role in impulsivity and working memory. 62 For example, recent findings demonstrated that D 4 receptors in hippocampal neurons can decrease NMDA receptor activity 66 and inhibit glutamatergic signaling in the frontal cortex. 67 In addition, D 4 antagonists were observed to reverse phencyclidineinduced cognitive impairment in monkeys, 68 together suggesting that D 4 receptor-selective agents may be valuable in the treatment of the cognitive deficits in schizophrenia.
Catechol-O-methyltransferase
Catechol-O-methyltransferase (COMT) is a postsynaptic enzyme that methylates and thereby deactivates synaptically released catecholamines, particularly dopamine. 69 Historically, monoamine oxidase was considered the primary enzyme for the initial deactivation of synaptic dopamine, 70 though mounting evidence suggests that COMT may be especially important for the breakdown of dopamine, particularly in the prefrontal cortex. 71 For example, COMT knockout mice show increased baseline levels of dopamine, but not other catecholamines such as norepinephrine, specifically in the frontal cortex. 72 In addition, the COMT knockout mice also showed enhanced memory performance, 72 suggesting a potential role of COMT inhibition in improving cognition. Indeed, a selective, reversible inhibitor of COMT, tolcapone, has been reported to improve working memory in rodents 73 and has been shown to improve cognitive dysfunction in patients with advanced Parkinson's disease, 74 though use is limited due to a risk of liver failure. 75 Other COMT inhibitors are currently being investigated for treatment of the cognitive dysfunction in schizophrenia.
Interestingly, a common single-nucleotide polymorphism (SNP) in the gene encoding COMT (val108/158met) results in the transcription of a variant of the COMT enzyme with approximately 40% less enzymatic activity in humans. 76 The reduced activity associated with the met variant presumably results in greater availability of dopamine in the prefrontal cortex and, thus, may be linked to some aspects of cognition in humans. Furthermore, accumulating evidence predicts that patients with schizophrenia who have the met allele may have improved cognitive response to clozapine. 77 The potential of pharmacologic inhibition of COMT in the long-term treatment of the cognitive dysfunction in schizophrenia, however, remains to be determined.
Serotonergic approaches
As serotonin receptors have been postulated to play a critical role in the action of the atypical antipsychotic drugs, we will briefly review a few of the serotonin receptors that continue to be targets in drug development for schizophrenia.
Serotonin 5-HT 2A receptors
Since the report that the atypicals, as a group, bind with higher affinity to 5-HT 2A receptors than to dopamine D 2 receptors, 78,79 selective 5-HT 2A receptor antagonists have been extensively explored as putative antipsychotic drugs. Unfortunately, however, the 5-HT 2A selective compound M-100907, was discontinued after two Phase III trials found M-100907, although more effective than placebo, failed to reduce symptoms to the same extent as haloperidol. 80 A Phase II study of the 5-HT 2A/2C antagonist SR46349B (eplivanserin) showed efficacy similar to haloperidol and better than placebo. 81 Thus, it is now clear that while selective 5-HT 2A receptor antagonists may have antipsychotic properties, they are not superior to D 2 antagonists. It is likely that the predominant role of 5-HT 2A receptors in antipsychotic action is to modulate dopaminergic tone, particularly along the mesocortical pathway. 82, 83 However, these studies also provide insight into why compounds with more complex pharmacologic profiles are likely superior to the 'magic bullet' approach in the treatment of complex diseases such as schizophrenia.
31,45
Serotonin 5-HT 1A receptors In addition to antagonism of the 5-HT 2A receptor, the agonist effects of clozapine on 5-HT 1A receptors have been postulated to contribute to its superior efficacy. 84 Research has also demonstrated that 5-HT 1A receptor agonism may actually result from 5-HT 2A receptor antagonism suggesting that 5-HT 1A agonism alone may produce an atypical antipsychotic drug when coupled with weak D 2 antagonism. Indeed, aripiprazole, a D 2 receptor partial agonist, may owe some of its atypical properties to its net effect of weak D 2 receptor antagonism, 5-HT 2A receptor antagonism and 5-HT 1A receptor agonism. 32, 38, 85 As such, 5-HT 1A receptor modulation is most likely to play a role in regulating dopaminergic tone similarly to 5-HT 2A receptors, 83 thus contributing to atypicality. Particularly, 5-HT 1A receptor agonism has been suggested to enhance dopamine levels in the prefrontal cortex, 86 which may be related to the modest efficacy of many atypicals in treating the negative symptoms and cognitive dysfunction of schizophrenia. Thus far, attempts to develop medications combining 5-HT 1A receptor agonism with other receptor binding activities have not full replicated the superior clinical profile of clozapine, again highlighting the need for compounds with more complex pharmacologic profiles.
31
Serotonin 5-HT 2C receptors Serotonin 5-HT 2C receptors are found at high densities in the ventral tegmental area and the substantia nigra, among other sites, where they tonically inhibit dopamine release. 83 Indeed, 5-HT 2C receptor agonists have been shown to decrease dopamine levels in the mesolimbic and mesocortical, but not nigrostriatal pathways, 83, 87 suggesting that 5-HT 2C agonists may have antipsychotic potential without causing EPS. Interestingly, a moderately selective 5-HT 2C agonist was recently shown to have antipsychotic-like effects on a battery of preclinical rodent models, including inhibition of conditioned avoidance response and amphetamine-induced hyperactivity, without inducing EPS. 88 Additionally, the weight gain and metabolic syndrome seen with administration of many of the atypical antipsychotics is thought to be due in part to antagonism of 5-HT 2C , as well as histamine H 1 receptors (Table 2) . 89, 90 Indeed, 5-HT 2C agonists have been shown to reduce food intake and body weight in humans. 91 However, a high degree of selectivity for 5-HT 2C receptors is absolutely critical, as stimulation of 5-HT 2A receptors may exacerbate psychosis and stimulation of 5-HT 2B receptors is thought to be the cause of the cardiac valvulopathy seen with fenfluramine and ergot-derived dopamine agonists. 92 An additional concern is that suppression of dopaminergic neurotransmission along the mesocortical pathway may be detrimental to cognition. Overall, 5-HT 2C receptor agonists show promise as antipsychotic and/ or anorexic agents, though a high level of receptor selectivity will be crucial.
Serotonin 5-HT 4 receptors
Serotonin 5-HT 4 receptors are found at high densities in the hippocampus, frontal cortex and amygdala, suggesting a role of these receptors in cognitive functions. 93 Indeed, 5-HT 4 receptors have been shown to be markedly decreased in patients with Alzheimer's disease 94 and 5-HT 4 receptor agonists have shown promise in the improvement of cognitive function by enhancing cholinergic transmission in the hippocampus, 93 and are thus being developed for the treatment of Alzheimer's disease. Interestingly, a recent study showed that the activation of 5-HT 4 receptors in a neuronal culture inhibited the secretion of b-amyloid peptide and enhanced neuronal survival. 95 While 5-HT 4 receptor-selective agonists are mostly being studied for their role in the treatment of Alzheimer's disease, they may also be of benefit in the treatment of the cognitive dysfunction in schizophrenia.
Serotonin 5-HT 6 receptors As several atypical antipsychotics, including clozapine and olanzapine exhibit high nanomolar affinity for 5-HT 6 receptors, 96 significant efforts have been made to understand its possible role in schizophrenia and other neuropsychiatric disorders. 97 Studies in rodents have suggested a role for 5-HT 6 receptors in the control of cholinergic neurotransmission, 98 and the selective 5-HT 6 receptor antagonist SB-271046 has been shown to improve memory retention in the water maze test of spatial learning and memory. 99 Thus, 5-HT 6 receptors may have an important future role in the treatment of cognitive deficits in neuropsychiatric illnesses such as Alzheimer's disease and schizophrenia.
Other monoaminergic approaches a 2 adrenergic receptors In the prefrontal cortex, a 2 adrenergic receptors appear to play an important role in cognitive functioning. 100 Indeed, treatment with the a 2 adrenergic receptor agonists clonidine and guanfacine has been shown to improve cognitive performance in small trials of patients with schizophrenia. 101, 102 In addition, patients randomized to risperidone plus guanfacine showed significant improvement on tasks of working memory and attention compared with patients receiving typical antipsychotics plus guanfacine. 102 Thus, a 2 adrenergic receptor activity is likely to be important in the development of new drugs for schizophrenia that can improve cognition. Complicating the picture, however, is the fact that clozapine and other atypicals have potent antagonist properties at a 2 adrenergic receptors, 103 which may contribute to the atypicality of atypicals by preferentially enhancing dopaminergic transmission in the frontal cortex over subcortical dopaminergic pathways. 104 Indeed, combined treatment of a selective a 2 adrenergic receptor antagonist with a typical antipsychotic drug has been reported to produce a profile of antipsychotic activity similar to clozapine. 105 Thus, balancing a 2 adrenergic receptor activity to achieve both antipsychotic and pro-cognitive efficacy may be challenging.
Cholinergic approaches
Acetylcholine is known to play an important role not only in motor function, but also in various domains of cognition, particularly attention, learning, and memory. 106 Indeed, cholinergic dysfunction has been shown to be central to the pathophysiology of Alzheimer's disease and has also been postulated to contribute to the cognitive deficits of various neuropsychiatric disorders, including schizophrenia. 107 Cholinesterase inhibitors, such as donepezil and rivastigmine, are currently the main pharmacologic approach to the treatment of Alzheimer's disease and have been shown to slow the cognitive decline in this neurodegenerative disease. 108 As such, it has been proposed that cholinesterase inhibitors may also be useful in the treatment of the cognitive dysfunction in schizophrenia. 109 Indeed, there have been multiple small randomized-controlled trials of cholinesterase inhibitors in patients with schizophrenia, though results have been disappointing. 110 In addition to cholinesterase inhibitors, significant efforts are underway to explore the modulation of various subtypes of both muscarinic and nicotinic acetylcholine receptors in the treatment of schizophrenia.
Muscarinic acetylcholine receptors
Of the five known muscarinic acetylcholine receptors (M 1 -M 5 ), the M 1 receptor has been most closely linked to cognition and schizophrenia. 111 For example, decreased M 1 receptor binding has been reported in postmortem studies of the prefrontal cortex, hippocampus, and striatum from patients with schizophrenia, 111 suggesting that M 1 receptor agonism might by beneficial in treating the cognitive dysfunction in schizophrenia. 111 Indeed, the salutary actions of clozapine on cognition have been hypothesized to be due in part to action at M 1 receptors. 112 However, studies have variably reported clozapine to be both an agonist and an antagonist at M 1 and other muscarinic receptors. 111 Interestingly, the major active metabolic of clozapine, N-desmethylclozapine, has been reported to be a potent M 1 agonist that preferentially binds to M 1 receptors versus clozapine 113 although more comprehensive studies fail to demonstrate selectivity of N-desmethylclozapine for M 1 receptors. 42 In addition, N-desmethylclozapine has high affinities for 5-HT 2A and 5-HT 2C receptors, and is a partial D 2/3 receptor agonist, 41, 43 suggesting that this metabolite of clozapine may also have antipsychotic and cognitionenhancing properties. Indeed, N-desmethylclozapine (ACP-104) and other M 1 receptor agonists are in clinical trials as potential treatments of the cognitive dysfunction in schizophrenia.
Xanomeline, a non-selective muscarinic agonist with potent actions at a variety of non-muscarinic GPCRs including 5-HT 1A and 5-HT 2A receptors 114 improved cognition and psychotic-like symptoms in Alzheimer's disease, but was discontinued due to poor tolerability. 115 The relatively non-selective actions of xanomeline at a number of GPCRs (http:// pdsp.med.unc.edu/pdsp.php) should engender caution among schizophrenia researchers for embracing positive data from xanomeline studies as being specifically indicative of a role for M 1 receptors in schizophrenia. Indeed, as muscarinic receptor subtype selectivity has been difficult to attain, allosteric modulators of muscarinic receptors are being extensively developed and explored as potential therapeutic agents. 116 Overall, evidence suggests that selective M 1 receptor agonists or positive allosteric modulators could be useful in treating various symptom domains in schizophrenia, though the roles of the other muscarinic receptor subtypes are less clear.
Nicotinic acetylcholine receptors
It is well known that the smoking rates in individuals with schizophrenia are significantly higher than in the general population and some have suggested that these individuals may be 'self-medicating' with nicotine. 117 Indeed, nicotine administration has been shown to improve various measures of cognition and may ease some of the side effects of antipsychotic medications. 117 Thus, considerable research has explored the potential use of nicotinic agents for the treatment of schizophrenia, specifically selective agonists and antagonists at various subunits of the nicotinic acetylcholine receptor. For example, the a 7 nicotinic receptor subtype modulates auditory gating, a process known to be deficient in schizophrenia 118 and agonists at a 7 receptors such as 3-2,4-dimethoxybenzylidene anabaseine (DMXB-A) can normalize the auditory gating deficits in rodents. 119 Moreover, DMXB-A had a positive effect on a cognitive battery in a small proof-of-concept trial in humans, 120 and additional clinical trials of a 7 receptor agonists are underway. However, long-term use of a 7 agonists may induce the desensitization of nicotinic receptors, leading to a limited duration of efficacy. 118 It has also been suggested that a 4 b 2 nicotinic receptors are involved in cognition, and agonists of a 4 b 2 receptors such as RJR 2403 can produce significant and long-lasting improvement of memory in rats. 121 Thus, nicotinic a 4 b 2 receptor agonists may be of therapeutic benefit for the treatment of the cognitive deficits in schizophrenia. In addition, allosteric modulators of nicotinic receptors are being explored as therapeutic agents. For example, galantamine is a positive allosteric modulator of nicotinic receptors in addition to being an acetylcholinesterase inhibitor. 118 The allosteric interaction of galantamine with nicotinic receptors can enhance the channel activity induced by a receptor agonist, either endogenous acetylcholine or theoretically a co-administered subtype-selective agonist.
Glutamatergic approaches
Since the 1950s, the N-methyl-D-aspartate (NMDA) glutamate receptor antagonists phencyclidine (PCP) and ketamine were known to produce a large range of schizophrenia-like symptoms including psychotic symptoms, negative symptoms, and cognitive dysfunction. 122 Thus, it has been hypothesized for decades that some deficiency in NMDA function might play a role in the pathophysiology of schizophrenia 122 and that drugs that can augment NMDA receptor activity may have therapeutic potential in schizophrenia. It is also important to note that a competing hypothesis suggests that a hyperactivity, not deficiency, of glutamatergic neurotransmission is involved in the psychopathology of schizophrenia, leading to seemingly contradictory pharmacologic approaches being explored. 122 Below, we briefly review various approaches being explored for modulating NMDA receptor neurotransmission and discuss approaches aimed at other glutamatergic mediators.
NMDA glutamate receptors NMDA glutamate receptors are ligand-gated ion channels with a primary glutamate binding site and an allosteric glycine binding site. 122 Interestingly, the opening of the NMDA channel appears to require both glutamate and glycine binding and can be modulated by multiple substances, including Mg 2 þ , polyamines, and protons, at various allosteric sites. 122 Thus, there are multiple potential sites to target for enhancing NMDA receptor activity; however, direct agonists of the glutamate binding site of the NMDA receptor may not be clinically feasible due to the risk of excess excitation causing neurotoxicity and seizures. Therefore, the allosteric sites on the NMDA receptor complex, particularly the glycine binding site have been targeted for development of pharmacotherapy in schizophrenia.
Compounds that target the glycine site of the NMDA receptor complex have been studied in multiple small clinical trials and include the amino acids glycine, D-cycloserine, D-serine, and D-alanine. 123 In most of these studies, the test compound was administered along with either a typical or atypical antipsychotic, and there appears to be significant benefits in reducing negative symptoms and cognitive impairment in patients with schizophrenia. 123 Of the four agents, D-cycloserine has been the least efficacious, likely due to it being a partial agonist that acts as an antagonist at high doses. Interestingly, when used concurrently with clozapine, glycine 124 and D-serine 125 have been reported to be ineffective while D-cycloserine seemed to worsen symptoms, 126 possibly because clozapine may already enhance glycine and glutamate neurotransmission. Overall, agonists at the glycine allosteric site of the NMDA glutamate receptor hold promise in the treatment of the negative and cognitive symptoms of schizophrenia, possibly as an augmentation of currently existing antipsychotics.
Glycine transporter
Another strategy being explored to boost NMDA activity at the glycine allosteric site is to increase synaptic glycine by inhibiting the glycine transporter. The use of glycine transport inhibitors would have the advantage of avoiding the very high doses of glycine and D-serine that are needed. Indeed, preclinical data suggest that inhibition of glycine reuptake represents a feasible approach to enhance NMDA receptor activity and possibly be therapeutic in schizophrenia. 122 For example, selective, highaffinity inhibitors of the glycine transporter, including Org-24598, 127 N-[3-(4 0 -fluorophenyl)-3-(4 0 -phenylphenoxy)propyl]sarcosine 128 and SSR-504734 have been found to reverse PCP-induced hyperactivity and dopaminergic hyperreactivity in rodents. 127, 128 Clinical trials to date, however, have only studied the low potency glycine transport inhibitor sarcosine (N-methyl glycine). In a clinical trial of sarcosine added to the stable antipsychotic regimen of patients with schizophrenia, there was a highly significant reduction in negative symptoms, along with smaller but significant reductions in positive and cognitive symptoms. 129 Interestingly, a subsequent study with patients on clozapine, found no improvement of symptoms with the addition of sarcosine, a result similar to studies with the NMDA glycine site agonists. 130 These results strongly suggest a role of glycine transport inhibitors in the treatment of schizophrenia, though results of trials with selective, high-potency inhibitors are anticipated.
Metabotropic glutamate receptors
Agents acting at metabotropic glutamate receptors (mGluR) are currently in preclinical development. Specifically, there are two main groups of mGluRs being studied in schizophrenia, Group I receptors include mGluR1 and mGluR5 and Group II receptors include mGluR2 and mGluR3. 131 Group I receptors increase presynaptic glutamate release while Group II receptors inhibit presynaptic glutamate release, however, agonists at each are being explored as potential treatments in schizophrenia demonstrating the duality of glutamatergic hypotheses in the pathophysiology of schizophrenia. 132, 133 Indeed, both approaches have shown efficacy in preclinical models of schizophrenia, 122 however, development of selective agents at mGluR subtypes has been an issue. Allosteric modulators of mGluRs hold promise as therapeutic agents and several groups have recently developed highly selective allosteric potentiators of these receptors. 133, 134 These selective allosteric modulators of mGluRs compounds may prove beneficial in the treatment of schizophrenia and preliminary positive results with an mGluR2 agonist in Phase II trials have been reported (http://newsroom.lilly.com/ReleaseDetail. cfm?ReleaseID = 221389).
Other ionotropic glutamate receptors
Another glutamatergic approach to drug development in schizophrenia has been the development of compounds that stimulate AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and kainate glutamate receptors. AMPA receptors help to activate NMDA receptors while NMDA receptors are required for proper incorporation of AMPA receptors into the postsynaptic membrane, a process involved in synaptic plasticity. 135 Direct AMPA receptor agonists rapidly desensitize AMPA receptors limiting their therapeutic utility, therefore, allosteric potentiators of AMPA receptor function, a class of compounds termed ampakines, are being studied as potential treatments for schizophrenia. 135 Ampakines can enhance glutamatergic transmission, facilitating longterm potentiation, learning and memory in rodents and may avoid the desensitization frequently seen with direct AMPA agonists. 135 In a clinical trial of schizophrenic patients on clozapine, coadministration of the ampakine CX-516 yielded significant improvements in memory and attention; 136 however, a trial of CX-516 as monotherapy in schizophrenia showed no clear beneficial effects. 137 Importantly, higher potency ampakines are currently under clinical development as both monotherapy for schizophrenia and adjunctive treatment for cognitive dysfunction, though results of trials are not yet available. An initial trial with Org24448 has been planned for cognition enhancement in schizophrenia (NCT00425815) though progress has not yet been reported for this compound.
In apparent contrast to the postulated utility of positive allosteric modulators of AMPA receptors as antipsychotics, preclinical data also paradoxically suggest that AMPA receptor antagonists may have antipsychotic efficacy. For example, the AMPA receptor antagonist, LY-326325 was shown to attenuate amphetamine-induced stereotypy 138 and suppress conditioned avoidance response in rats. 139 In addition, administration of the AMPA/kainate receptor antagonist, LY-293558, partially reversed the impairment of working memory induced by subanesthetic doses of ketamine in rats 140 suggesting a possible utility of AMPA antagonists in the treatment of the cognitive deficits in schizophrenia, though further research is indicated. 40 Overall, it remains unclear if modulation of AMPA receptors by agonists, antagonists or allosteric modulators such as ampakines has therapeutic value in the treatment of schizophrenia although this is a highly active area of research.
Other approaches

Cannabinoid receptors
A recent meta-analysis demonstrated a statistically significant correlation of prior cannabis use and the development of schizophrenia 141 adding to a large amount of evidence implicating the endogenous cannabinoid system in schizophrenia. 142 The endogenous cannabinoid system contains at least two cannabinoid receptors, the CB 1 and CB 2 receptors. A selective CB 1 receptor antagonist, SR-141716 showed activity in preclinical models of antipsychotic efficacy, 143, 144 however, in a recent clinical trial, SR-141716 failed to demonstrate antipsychotic efficacy versus placebo. 81 Whether further clinical trials with cannabinoid receptor antagonists in schizophrenia are warranted is debatable.
Neurokinin receptors
Neurokinin 1 (NK 1 ) and neurokinin 3 (NK 3 ) receptors have been explored as potential targets for neuropsychiatric drug development. [145] [146] [147] NK 1 receptor antagonists may have efficacy in the treatment of depression, though a recent clinical trial of the NK 1 -selective antagonist, aprepitant, for depression did not show efficacy versus paroxetine.
148 NK 3 receptor antagonists, however, have been investigated as potential antipsychotic agents as NK 3 receptors appear to regulate midbrain dopaminergic function. 149 As such, several NK 3 receptor antagonists, including osanetant and talnetant, have been in development as potential treatments for schizophrenia. In a recent clinical trial, osanetant showed statistically significant improvement in positive symptoms and global assessment versus placebo and was similar to haloperidol; 81 however, an informal report of a follow-up study indicated negative results and the compound was discontinued. 149 No clinical trial data have been published to date on talnetant and trials in schizophrenia appear to have been discontinued; thus whether NK 3 receptor antagonists may serve as novel antipsychotics either as monotherapy or as augmentation for the treatment of negative symptoms or cognition remains to be determined.
Neurotensin receptors
Neurotensin (NT) is a neuropeptide that, for decades, has been implicated in the pathophysiology of schizophrenia as it is closely associated with, and modulates dopaminergic and other neurotransmitter systems. 150 Indeed, significant preclinical data suggested a potential use of NT receptor agonists as novel therapeutic agents for the treatment of schizophrenia. 150 For example, administration of NT agonists, such as PD-149163, can reverse amphetamine-induced effects on hyperactivity and prepulse inhibition without inducing catalepsy. 151 Thus, NT receptor agonists likely have potential in the treatment of schizophrenia; however, there have been no published clinical trials of NT agonists. Interestingly, there is also seemingly contradictory evidence indicating that NT antagonists may have antipsychotic potential as there may be pathologically increased NT tone in schizophrenia. 150 A recent clinical trial, however, showed no antipsychotic efficacy of a potent and selective NT 1 receptor antagonist, SR-48692, compared with placebo. 81 Thus, NT antagonists may not be useful for the treatment of schizophrenia; however, clinical trials of NT agonists are needed to explore this novel treatment strategy for schizophrenia.
Additional approaches A number of other approaches for the development of novel therapeutics for the treatment of schizophrenia have been described including, cyclooxygenase-2 (COX2) inhibitors, phosphodiesterase 10A (PDE10A) inhibitors, neurosteroids, and secretin. COX-2 inhibitors such as celecoxib have been hypothesized to improve cognitive performance by reducing inflammatory processes in the central nervous system. 152 Indeed, in one small trial, there was some significant benefit with the addition of celecoxib to risperidone. 153 PDE10A is a recently identified phosphodiesterase expressed at high levels in the brain and PDE10A inhibitors have been shown to antagonize the effects of both amphetamine and phencyclidine in rodents suggesting antipsychotic potential. 154 Secretin is a gastrointestinal peptide that has poorly defined roles in the brain, however, recent studies have suggested a possible therapeutic benefit in autism and transient improvement of symptoms in schizophrenia, 155 though repeated intravenous administration is likely to limit therapeutic potential.
Neurosteroids, such as dehydroepiandrosterone (DHEA), 156 pregnenolone 157 and their derivatives have been implicated in neuroprotection and enhancement of NMDA receptor neurotransmission suggesting therapeutic potential in schizophrenia, 40 possibly by actions at sigma1 receptors. 156, 157 Indeed, a doubleblind study of DHEA as an adjunct to antipsychotic treatment in chronic schizophrenic patients with prominent negative symptoms suggests some efficacy at improving negative symptoms, especially in women, 158 though further studies are needed.
Moving towards the future
As is apparent from the preceding sections, most of the current strategies for developing novel compounds for the treatment of schizophrenia have not been successful. All currently available medications target D 2 dopamine receptors-a paradigm that has dominated drug development for the past 20 yearsand many have been identified by activity in preclinical models that were devised based on pharmacologic manipulation (such as psychostimulant-induced behaviors). Indeed, these models have helped identify additional antagonists at dopamine D 2 and serotonin 5-HT 2A receptors, and are helping to identify novel neurotransmitter approaches to modulate dopamine. In addition, the development of highly selective agents for various neurotransmitter receptor targets has been and will continue to be extremely valuable in the elucidation of brain physiology and the understanding of the pathophysiology of complex disorders such as schizophrenia; however, future drug discovery approaches will have to be truly revolutionary and based on a better understanding of the pathogenesis of the disease. Interestingly, we are in an era of increased knowledge and enormous spending in biomedical research but a dearth of advances in therapeutics. This decrease in the introduction of fundamentally new drugs into clinical practice is evidence of attempts to make a fundamental shift in the basic paradigms used for drug discovery. Thus, this is an exciting and pivotal time for the development of truly novel approaches to drug development and treatment of complex disorders like schizophrenia. Below, we will discuss some of the exciting advances in our understanding of the pathophysiology of schizophrenia, will highlight some novel strategies currently being explored for drug development, and will stress the need for an increased role of academic scientists in target identification and validation.
Models of the pathophysiology of schizophrenia A major critique of current drug discovery approaches for schizophrenia is that adequate treatments cannot be developed because the underlying causes of major mental illnesses remain incompletely understood. 21, 31, 159 Indeed, while there have been enormous advances in our understanding of the basic biological processes contributing to many human diseases, a detailed understanding of the processes underlying schizophrenia and other complex mental disorders remains elusive. With the sequencing of the human genome and the development of genomics-based technologies, there are unprecedented opportunities for gaining fundamental new insights into these complex diseases. 160 Currently, at least three highly overlapping hypotheses of the underlying pathophysiology of schizophrenia drive drug discovery efforts. 16 The first hypothesis, and the one that accounts for all of the current antipsychotic medications and the vast majority of compounds in the pipeline, is the signal transduction hypothesis, which posits that basic alterations in receptor-medicated signal transduction induces schizophrenia-like psychopathology. Therefore, normalizing the altered signaling with medications targeting receptor and post-receptor molecules should be efficacious in treating schizophrenia. 122, 161 Indeed, targeting these neurotransmitter receptor sites has, to this point, been the predominate focus of psychopharmacological research, and this strategy has led to significant advances in our understanding of the pathophysiology of schizophrenia and brain function as a whole. Future efforts, however, should move beyond the current strategies of solely targeting the synaptic neurotransmission at the receptor level to the development of agents that can affect more diverse cellular functions including intracellular signaling pathways and the mechanisms involved in synaptic plasticity.
Second, the molecular-genetic hypothesis posits that strong effects of susceptibility genes underlies the pathophysiology of schizophrenia, 162 and suggests that targeting drugs at these genes or their associated anatomic and functional pathways might yield novel and more effective treatments for schizophrenia. 163, 164 Indeed, significant progress has been made in recent years on elucidating various susceptibility genes in schizophrenia, including dysbindin, neuregulin 1, COMT, DISC1, and others. 165 Interestingly, many of these genes appear to be related to the control of synaptic plasticity and glutamate transmission (particularly NMDA receptor function) (Figure 1 ). These recent breakthroughs in genetic studies of schizophrenia begin to allow for hypothesis-driven approaches for developing actual disease-modifying drugs for schizophrenia. In addition, individualized treatment strategies could be developed that are focused on subgroups of schizophrenic patients with specific susceptibility alleles.
A third hypothesis, the neural network hypothesis, proposes that schizophrenia results from the strong effects of altered neuronal integration. This hypothesis predicts that drugs that fundamentally reset the tone of networks of neuronal interactions will prove efficacious in treating schizophrenia. 159, 166 Indeed, significant evidence exists suggesting that schizophrenia is a neurodevelopmental disorder associated with abnormal connectivity resulting from defects in synaptic pruning and migration of neurons. 167 Thus, if alterations in synaptic pruning are the primary process underlying the pathophysiology of schizophrenia, possibly due to inherited genetic alterations in genes such as DISC1 or dysbindin, then effective treatment strategies should target the underlying deficits ( Figure 1 ). In addition, successful treatment of schizophrenia may then require early recognition and treatment during or even before an obvious prodromal stage. However, if the underlying defects are due to abnormal migration of cortical neurons and subsequent dysregulation of cortical development, it may be impossible to ameliorate such deficits via simple pharmacological approaches.
Challenges of future drug discovery While there has been significant progress in our understanding of the underlying pathophysiology of schizophrenia, a great deal of additional research is needed before we can begin the systematic development of drugs that may address the root cause of the disease. Thus, before our full understanding of those causes, the development of novel drugs with superior efficacy and improved side-effect profiles is still essential. It has been suggested that 'selectively nonselective' drugs, or 'magic shotguns,' can already be developed and may fill a clinical need for improved therapeutics. 31, 44 Indeed, genomics-based screening approaches are being used to identify novel drug candidates based on their ability to either mimic the gene expression 'signature' of gold-standard drugs like clozapine, or based on their ability to normalize the expression of genes that are altered in schizophrenia. 45 Alternatively, high-throughput behavioral screenings may prove useful for the identification of novel medications for schizophrenia, 45 though hurdles exist in finding animal behavioral models with good predictive value.
Indeed, while current preclinical models for schizophrenia are quite effective at predicting whether a candidate molecule will have 'atypical' properties, they are less able to predict overall efficacy and are completely unable to predict greater efficacy than currently available antipsychotics. In addition, none of the available animals models accurately predict the propensity of various antipsychotic drugs to induce weight gain and associated side effects, although some of this can be predicted based on knowledge of in vitro receptor pharmacology. 90 Moreover, in terms of the negative and cognitive symptom domains in schizophrenia, none of the commonly used animal models are highly predictive, although preclinical memory models may be useful for predicting ability to enhance cognition. This lack of predictive, reliable and efficient animal models has severely hindered progress in discovering novel therapeutics for schizophrenia, highlighting a need for increased collaboration between scientists in academic settings and industry. Thus, we advocate that academic-based scientists should be more aggressively involved in contributing to the drug discovery process, particularly by focusing on target validation 15 ( Figure 2) . This challenge will require increased collaboration with the pharmaceutical industry as well as priority by the NIMH to fund such endeavors.
Conclusions
In the past 20 years, new therapies for schizophrenia have primarily emerged from a quest to discover new drugs that lack the extrapyramidal side effects of the typical antipsychotic drugs. While the atypical antipsychotics have probably been of some benefit to patients, due to their somewhat improved therapeutic margin and efficacy at treating the negative symptoms of schizophrenia, this modest benefit has been tempered by their own troublesome side-effect profiles, including weight gain and diabetes-likely due to off-target actions at therapeutically irrelevant receptors. 90, 168 Thus, we have reached a significant bottleneck in the drug discovery process due to incomplete understanding of the mechanisms of action of the currently available antipsychotics as well as poorly defined pathophysiology for this complex and likely heterogeneous disorder. Interestingly, as many of the atypicals will soon go off patent, there is increased urgency within the pharmaceutical industry to develop new, novel treatments for schizophrenia.
We predict that the future of pharmacologic treatment of schizophrenia will likely start with the continued use of polypharmacy and augmentation strategies aimed at treating the multiple symptom domains of schizophrenia. This may be followed by the development of selectively nonselective single compounds that can target multiple domains at once while simultaneously decreasing side effects, eliminating potential pharmacokinetic interactions and improving medication compliance. 31, 45 The long-term goal, of course, will be to develop 'cure therapeutics' 164 which will likely require a substantial shift in the current paradigm of drug development and significant advances in our understanding of the pathophysiology of schizophrenia. Thus, it is important to continue to pursue diverse molecular targets and increase efforts at validating novel targets. Indeed, recent breakthroughs in genetic studies of schizophrenia have provided renewed excitement for the development of drugs at novel targets that may target underlying disease processes. This shift in our approach to drug development will require considerable contributions from academic-based researchers as well as bold and potentially risky endeavors by the pharmaceutical industry. Figure 2 Continuous target validation in academia. Identifying and validating novel targets is a significant rate-limiting step in new drug development which has led to few new drugs with truly novel mechanisms of action. Thus, increased research in the academic setting is needed to identify selective compounds for novel targets that may be used for testing hypotheses at these targets and for proof of concept experiments. Continuous validation of targets by academic scientists at each step in the drug development process, including proof of concept experiments in the clinical setting, may facilitate the development of fundamentally new therapeutics for schizophrenia. Adapted from BL Roth and PJ Conn: IOM White Paper, 2006.
